3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Endometrial Neoplasms
3
Breast Neoplasms
3
Ovarian Neoplasms
2
Non Small Cell Lung Carcinoma NSCLC
2
Neoplasms
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcopenia
1
Penile Neoplasms
1
Non-Small Cell Lung Cancer With HER2- Mutations
1
Malnutrition
1
Male Urogenital Diseases
1
Lung Neoplasms
1
First-line Advanced NSCLC Patients
1
Fallopian Tube Neoplasms
1
Dysgeusia
1
Carcinoma
1
Interventions
fludarabine
4
Cyclophosphamide
4
Cisplatin
4
pembrolizumab
3
atezolizumab
3
Pemetrexed
3
fludarabine phosphate
2
entrectinib
2
durvalumab
2
cobimetinib
2
capmatinib
2
alectinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Paclitaxel
2
Nivolumab
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
spartalizumab
1
ruxolitinib
1
repotrectinib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
CP protocol
×
1 year
×
Clear all
No trials found.